Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with 4hydroxycyclophosphamide formation in children with Cancer.

Cancer chemotherapy and pharmacology - 1 Oct 2024

Navarro Sandi L, Pinto Navin, Hawkins Douglas S, Park Julie R, Dilmaghani Saam, Rimorin Christine, Wurscher Michelle, McCune Jeannine S

Abstract excerpt

PURPOSE: 4-hydroxycyclophosphamide (4HCY) is the principal precursor to the cytotoxic metabolite of cyclophosphamide (CY), which is often used as first-line treatment of children with cancer. There is conflicting data regarding the relationship between CY efficacy, toxicity, and pharmacokinetics with the genes encoding proteins involved in 4HCY pharmacokinetics, specifically its formation and elimination....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Cyclophosphamide

Share to Infant

Share to Neoplasms

Share to Pharmacogenetics

Source

Open in PubMed Open full text

Identifiers

PMID: 39080017
DOI: 10.1007/s00280-024-04703-2
PMCID: PMC11438565

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with 4hydroxycyclophosphamide formation in children with Cancer.PMID 39080017Read ↗

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesSemantic proximity Read ↗

Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.Semantic proximity Read ↗

Pharmacogenomics in pediatric leukemia.Semantic proximity Read ↗

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.Semantic proximity Read ↗

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.Semantic proximity Read ↗

Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and ResponseSemantic proximity Read ↗

Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients.Semantic proximity Read ↗

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastomaSemantic proximity Read ↗

Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.Semantic proximity Read ↗

Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patientsSemantic proximity Read ↗

Effects of gene polymorphisms on delayed MTX clearance, toxicity, and metabolomic changes after HD-MTX treatment in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Cyclophosphamide pharmacogenomics and their effect on its bioactivation and pharmacokineticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.